Skip to content

Serotonin: all studies

Page 267 of 401: studies 2,661 to 2,670 of 4,006, newest first. Back to the serotonin overview

Research

La ciencia psicodélica del siglo XXI

Vertex Revista Argentina de Psiquiatría July 10, 2023 Nahuel Enrique Baca 1 citation

We are currently witnessing a renaissance of psychedelic science in clinical research. In Argentina, the challenges related to its study and the development of new treatments in the field of Psychiatry are subject to the adoption of certain regulatory policies. The evolution of the knowledge about the effects, mechanisms of action and therapeutic potential of serotonergic psychedelics warrants...

DOI: 10.53680/vertex.v34i160.461 (opens in new tab) The renaissance Politics Subject documents Flexibility engineering +5

[Psychedelic Experiences: Phenomenology, Therapeutic Potentials and Explanatory Models].

Vertex Revista Argentina de Psiquiatría July 10, 2023 Tamara Chernoff, Bruno Kliger, Dante Hernán Venturini

Traditional psychedelics, such as LSD, psilocybin, or DMT, are psychoactive compounds that exert their effects mainly through agonism over serotonergic receptors. In appropriate doses and contexts, they produce profound changes in the subjective experience, configuring altered states of consciousness that, upon reaching a critical point, involve the appearance of phenomena of mystical,...

Overview of the synthetic approaches to lysergic acid as a precursor to the psychedelic LSD

Australian Journal of Chemistry July 7, 2023 Michael J. Nutt, Nick Woolf, Scott G. Stewart 2 citations

In this short primer we will discuss the total synthesis of lysergic acid, an important precursor to both lysergic acid diethylamide (LSD) and its derivatives. Lysergic acid is also noted as a precursor for many drugs targeting the serotonin receptor family of GPCRs, including multiple known hallucinogens. More recently, reinvigorated interest in the therapeutic potential of psychedelics from...

O uso de psilocibina é eficaz no tratamento de depressão?

Brazilian Journal of Health Review July 3, 2023 Edson Santana Gois Filho, Ana Letícia Fiscina Reis, Marco Antonio Galvão Martins de Farias et al. 1 citation

Os Inibidores da Recaptação de Serotonina (ISRS) foram descobertos na década de 1980 e, desde então, são a primeira linha para o tratamento da depressão. Nos últimos anos, pesquisas para busca de novas terapias farmacológicas vem tomando visibilidade com a descoberta dos efeitos antidepressivos dos psicodélicos. Dentro deles, destaca-se a Psilocibina, um alcalóide advindo do fungo Psilocybe...

Navigating the chaos of psychedelic fMRI brain-entropy via multi-metric evaluations of acute psilocybin effects

medRxiv July 3, 2023 Drummond E-Wen Mcculloch, Anders S. Olsen, Brice Ozenne et al. 20 citations preprint

A prominent theory of psychedelics is that they increase brain entropy. Twelve studies have evaluated psychedelic effects on fMRI brain entropy quantifications, no findings have been replicated. Here we evaluated these metrics in an independent 28-participant healthy cohort with 121 pre- and post-psilocybin fMRI scans. We assessed relations between brain entropy and plasma psilocin, brain...

DOI: 10.1101/2023.07.03.23292164 (opens in new tab) Full text (opens in new tab) Psilocybin Sample entropy Artificial intelligence Cognitive psychology +2

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial

BJPsych Open July 1, 2023 Allan H. Young, Wiesław Jerzy Cubała, René Ernst Nielsen et al. 2 citations

Aims For patients with depression, the likelihood of remission decreases with each subsequent treatment failure. Per European Medicines Agency guidance, treatment resistant depression (TRD) is defined as nonresponse to ≥2 consecutive treatments at adequate dosage and duration in the current depressive episode. In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) increased the probability of...

Neuromodulatory mechanisms of N,N-dimethyltryptamine

Brain Network and Modulation July 1, 2023 Javier Hidalgo Jiménez 2 citations

N,N-dimethyltryptamine (DMT) is the simplest psychedelic tryptamine and is produced naturally by many plant and animal species, including humans. While classical psychedelics, such as lysergic acid diethylamide, or psilocybin, are gaining interest because of their therapeutic potential, DMT has yet to be fully investigated. However, preliminary clinical evidence suggests that DMT and/or...

From recent advances in underlying neurocircuitry of fear and anxiety to promising pharmacotherapies for PTSD: The saga of heart, sex and the developing brain.

Neuropharmacology July 1, 2023 Joanna Dabrowska 6 citations

Available pharmacotherapies for anxiety disorders and post-traumatic stress-disorder (PTSD) have limited efficacy, but no new anxiolytic drug has been approved for treatment since the 1980s. In this issue of Neuropharmacology on "Fear, anxiety and PTSD: from cellular mechanisms to translational approaches", we review the currently recommended pharmacotherapy for PTSD and discuss promising...

Phytochemical interventions for post-traumatic stress disorder: A cluster co-occurrence network analysis using CiteSpace.

Journal of integrative medicine July 1, 2023 Biao Gao, Yi-Cui Qu, Meng-Yu Cai et al. 9 citations

This study investigated trends in the study of phytochemical treatment of post-traumatic stress disorder (PTSD). The Web of Science database (2007-2022) was searched using the search terms "phytochemicals" and "PTSD," and relevant literature was compiled. Network clustering co-occurrence analysis and qualitative narrative review were conducted. Three hundred and one articles were included in...

The molecular basis of the antidepressant action of the magic mushroom extract, psilocin.

Biochimica et Biophysica Acta. Proteins and Proteomics July 1, 2023 Ali Asghar Hakami Zanjani, Teresa Quynh Tram Nguyen, Luise Jacobsen et al. 6 citations

Magic mushrooms, and their extract psilocybin, are well-known for their psychedelic properties and recreational use. Psilocin, the bio-active form of psilocybin, can potentially treat various psychiatric diseases. Psilocin putatively exerts its psychedelic effect as an agonist to the serotonin 2A receptor (5-HT2AR), which is also the receptor for the neurological hormone serotonin. The two key...